CAS:1254044-38-6(11-((4-Hydroxy-3-methoxybenzoyl)oxy)undecyl)triphenylphosphonium bromide

您的位置 : 首页 / Metabolic Enzyme / Mitochondrial Metabolism / Mito-apocynin-C11

Mito-apocynin-C11 (11-((4-羟基-3-甲氧基苯甲酰基)氧基)十一烷基)三苯基溴化鏻 Cat No. FB16558Cas No. 1254044-38-6

Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP+ cation. Mito-apocynin (C11) selectively targets mitochondria, and shows neuroprotective effect. Mito-apocynin (C11) prevents hyposmia and corrects deficits in motor function .

规格	价格	促销价格	库存

18817579266

立即询价

咨询

18817579266

立即询价

实验数据

储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 1.5069 mL
- 7.5344 mL
- 15.0689 mL
- 5 mM
- 0.3014 mL
- 1.5069 mL
- 3.0138 mL
- 10 mM
- 0.1507 mL
- 0.7534 mL
- 1.5069 mL
计算器摩尔计算器总药量计算器工作液计算器

技术信息

CAS号	1254044-38-6	储存条件	粉末 -20°C 3 年液体 -80°C 12 月
分子式	C37H44BrO4P	运输	蓝冰
分子量	663.62	别名

靶点数据

生物活性

描述Parkinson's disease (PD) patients exhibit early non-motor symptoms that are considered “preclinical”, but are increasingly recognized for their diagnostic potential. Hyposmia (diminished ability to smell and detect odors) is an early sign of PD and other neurodegenerative diseases. Mito-apocynin-C11 is a novel mitochondrially-targeted apocynin derivative which prevents hyposmia and loss of motor function in the mouse model of PD. The presence of a highly lipophilic and delocalized cationic moiety in Mito-apocynin-C11 makes it more cell-permeable and selectively target mitochondria. LRRK2^R1441G transgenic or wild type littermates were orally gavaged with 3 mg/kg Mito-apocynin-C11 3x/wk from 3 months of age until 15 months. This treatment showed that Mito-apocynin-C11 administration markedly improved the coordinated motor function and olfactory function in LRRK2^R1441G mice. Notably, long-term treatment with Mito-apocynin-C11 prevented this hyposmia with performance remaining near the level of the wild type mice. Interestingly, the ability to remain on the spinning rod was retained in LRRK2^R1441G mice orally gavaged with Mito-apocynin-C11^[2].